Ladiratuzumab, CAS [[1629760-28-6]]

Produktübersicht

• Artikelname: Ladiratuzumab, CAS [[1629760-28-6]]
• Artikelnummer: MCE-HY-P99682
• Hersteller Artikelnummer: HY-P99682
• Alternativnummer: MCE-HY-P99682-1MG,MCE-HY-P99682-25MG,MCE-HY-P99682-5MG,MCE-HY-P99682-10MG
• Hersteller: MedchemExpress
• Kategorie: Antikörper
• Alternative Synonym: hLIV22

Produktbeschreibung

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC)[1][2].

Produkteigenschaften

• Molekulargewicht: (146.96 kDa)
• Reinheit: 99.95
• CAS Nummer: [1629760-28-6]
• Target-Kategorie: ADC Antibody

Anwendungsbeschreibung

• Anwendungsbeschreibung: MCE Product type: Inhibitory Antibodies